首页 | 本学科首页   官方微博 | 高级检索  
     


Preliminary evaluation of 177Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy
Authors:Lei Jiang  Zheng Miao  Richard H. Kimura  Hongguang Liu  Jennifer R. Cochran  Cathy S. Culter  Ande Bao  Peiyong Li  Zhen Cheng
Affiliation:(1) Department of Nuclear Medicine, Shanghai Ruijin Hospital, Shanghai Jiaotong University, 2nd Ruijin Rd, Shanghai, 200025, People’s Republic of China;(2) Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford Cancer Center, Bio-X Program, Stanford University, 1201 Welch Road, Lucas Expansion, P020A, Stanford, CA 94305, USA;(3) Department of Bioengineering, Stanford Cancer Center, Bio-X Program, Stanford University, Stanford, CA 94305, USA;(4) Research Reactor Center, University of Missouri, Columbia, MO 65211, USA;(5) Departments of Radiology and Otolaryngology – Head and Neck Surgery, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA;
Abstract:

Purpose  

Cystine knot peptides (knottins) 2.5D and 2.5F were recently engineered to bind integrin receptors with high affinity and specificity. These receptors are overexpressed on the surface of a variety of malignant human tumor cells and tumor neovasculature. In this study, 2.5D and 2.5F were labeled with a therapeutic radionuclide, 177Lu, and the resulting radiopeptides were then evaluated as potential radiotherapeutic agents in a murine model of human glioma xenografts.
Keywords:
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号